- Report
- February 2024
- 70 Pages
Malaysia
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 85 Pages
North America
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 100 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4533EUR$4,750USD£3,798GBP
- Report
- March 2019
- 90 Pages
Europe
From €4533EUR$4,750USD£3,798GBP
- Report
- December 2023
- 142 Pages
Brazil
From €2386EUR$2,500USD£1,999GBP
- Report
- January 2025
- 82 Pages
Vietnam
From €3340EUR$3,500USD£2,799GBP
- Report
- December 2024
- 85 Pages
Spain
From €3340EUR$3,500USD£2,799GBP
- Report
- August 2018
- 154 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- October 2020
- 133 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- November 2023
- 110 Pages
Global
From €2815EUR$2,950USD£2,359GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP

Within the field of endocrinology and metabolic disorders drugs, the basal insulin market is a prominent segment addressing the therapeutic needs of patients with diabetes mellitus, primarily type 1 diabetes and advanced type 2 diabetes. Basal insulin preparations are designed to be long-acting, maintaining consistent insulin levels in the bloodstream to control blood glucose throughout the day and night. These insulins aim to mimic the insulin secretion of a healthy pancreas and are typically administered once or twice daily.
The treatment paradigm for diabetes has evolved to prioritize individual patient needs, and within this context, basal insulins offer different profiles in terms of onset of action, peak activity, and duration of effect. Technological advancements have led to newer insulin analogs and delivery systems that seek to improve glycemic control and reduce the risk of hypoglycemia. Key challenges in the market include the management of therapy costs and ensuring accessibility to these life-sustaining drugs.
Prominent participants in the basal insulin market include Sanofi with its Lantus and Toujeo lines, Novo Nordisk offering Levemir and Tresiba, and Eli Lilly with the Basaglar and Humulin product families. These companies compete not only on efficacy and safety but also in areas such as pricing, delivery mechanisms, and patient support programs. Show Less Read more